Four reasons to subscribe for shares in UV Clinical A/S

UV Clinical’s patented UVC technology eliminates bacteria and biofilm forming on the inside of catheters and endotracheal tubes during treatment. Bacteria and biofilm often lead to serious, sometimes even fatal infections, especially in haemodialysis, cancer and ICU patients. Average costs of a catheter-related infection are USD 48,000.

UV Clinical’s technology saves lives and reduces treatment costs.


UV Clinical’s UVC technology is effective against all types of microorganisms. The technology delivers a constant disinfection UVC dose during treatment. UVC disinfection technology does not result in development of resistant pathogens.


The market potential is massive. UV Clinical’s disinfection technology can help patients from acquiring Catheter-Related Bloodstream Infection (CRBSI), caused by an intravenous catheter. In the US alone, CRBSI affects 80,000 patients annually. The technology can also help patients from acquiring Ventilator-Associated Pneumonia (VAP). There are 250,000 – 300,000 VAP patients in the US each year.


UV Clinical’s unique UVC solution is a platform technology that can be tailored for future applications for disinfection of tubing and confined spaces without the use of chemicals in a wide range of industries, including food and beverages, pharmaceuticals and drinking water.


UV Clinical is currently conducting a pre-IPO financing round with a company valuation of MDKK 17.2. The Company intends to execute an IPO at a higher valuation in the first part of 2023 in conjunction with a listing on the Spotlight Stock Market.

Want more information?

Send us your questions here